Warsaw, Poland

Dagmara Tymecka

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2019-2020

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Dagmara Tymecka: Innovator in Peptidomimetics

Introduction

Dagmara Tymecka is a prominent inventor based in Warsaw, Poland. She has made significant contributions to the field of pharmaceuticals, particularly in the development of cyclic peptidomimetics. With a total of two patents to her name, her work focuses on innovative treatments for diseases associated with angiogenesis.

Latest Patents

Dagmara's latest patents include "Cyclic peptidomimetics, compositions containing them and their use in the treatment of diseases associated with angiogenesis" and "Peptidomimetics with antiangiogenic activity." The first patent relates to novel cyclic peptidomimetics and their pharmaceutical compositions, which are aimed at treating various conditions such as tumors, chronic inflammation in psoriasis, diabetes, degenerative diseases of the eye, nephropathy, and neuropathy. The second patent discloses peptidomimetics with antiangiogenic activity, particularly useful in treating neoplasms and chronic inflammation, including rheumatoid arthritis and colitis.

Career Highlights

Dagmara Tymecka is affiliated with the University of Warsaw, where she continues her research and development in the field of pharmaceuticals. Her innovative work has positioned her as a key figure in the advancement of treatments for complex diseases.

Collaborations

She collaborates with notable colleagues such as Bartlomiej Fedorczyk and Piotr Sosnowski, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Dagmara Tymecka's contributions to the field of peptidomimetics highlight her role as an influential inventor in the pharmaceutical industry. Her work not only advances scientific knowledge but also offers potential solutions for treating serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…